MAZE Share Price Performance
US$27.86
11.91 (74.67%)
Price US$27.86
Share PriceUS$27.86
Maze Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
MAZE Community Narratives
There are no narratives available yet.
Maze Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.68
- Gross Margin
- 100.00%
- Net Profit Margin
- -2,951.92%
- Debt/Equity Ratio
- 0%
Maze Therapeutics, Inc. Competitors
Snowflake Analysis
About MAZE
- Founded
- 2017
- Employees
- 125
- CEO
- WebsiteView website
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.4%
- 3 Months: 7.8%
- 1 Year: 17.8%
- Year to Date: 14.7%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 3.7%. As for the longer term, the market has risen 18% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›